|Title:||HIV protease inhibitors|
|Abstract:||HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.|
|Inventor(s):||Dressman; Bruce A. (Indianapolis, IN), Fritz; James E. (Greenwoode, IN), Hammond; Marlys (Pasadena, CA), Hornback; William J. (Indianapolis, IN), Kaldor; Stephen W. (Indianapolis, IN), Kalish; Vincent J. (San Diego, CA), Munroe; John E. (Indianapolis, IN), Reich; Siegfried H. (San Diego, CA), Tatlock; John H. (Poway, CA), Shepherd; Timothy A. (Indianapolis, IN), Rodriguez; Michael J. (Indianapolis, IN)|
|Assignee:||Agouron Pharmaceuticals, Inc. (San Digeo, CA)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||600||► subscribe|
|African Regional IP Organization (ARIPO)||9600844||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.